UNLABELLED: SUMMARY AIMS: To investigate the effectiveness of N-palmitoylethanolamide (PEA) in the treatment of neuropathic pain due to lumbosciatica. MATERIALS & METHODS: Patients with neuropathic pain were assigned to standard treatment plus PEA (600 mg/day) or standard treatment for 30 days. Changes in visual analog scale, and score on Oswestry Disability Index and SF-12® Health Survey were assessed at baseline and follow-up. RESULTS: The mean age of the 118 patients evaluated was 48.4 years, and 47 (40.9%) were women. In the group comparison, significantly larger improvements were seen in the PEA group for visual analog scale and the physical component of the SF-12 Health Survey. CONCLUSION: The addition of PEA to standard treatment shows an improvement in pain relief in patients with neuropathic pain due to lumbosciatica. PEA was well tolerated. Future investigations of the role of PEA in the treatment of neuropathic pain might help to define novel therapeutic strategies for the treatment of this kind of neuropathic pain.
UNLABELLED: SUMMARY AIMS: To investigate the effectiveness of N-palmitoylethanolamide (PEA) in the treatment of neuropathic pain due to lumbosciatica. MATERIALS & METHODS:Patients with neuropathic pain were assigned to standard treatment plus PEA (600 mg/day) or standard treatment for 30 days. Changes in visual analog scale, and score on Oswestry Disability Index and SF-12® Health Survey were assessed at baseline and follow-up. RESULTS: The mean age of the 118 patients evaluated was 48.4 years, and 47 (40.9%) were women. In the group comparison, significantly larger improvements were seen in the PEA group for visual analog scale and the physical component of the SF-12 Health Survey. CONCLUSION: The addition of PEA to standard treatment shows an improvement in pain relief in patients with neuropathic pain due to lumbosciatica. PEA was well tolerated. Future investigations of the role of PEA in the treatment of neuropathic pain might help to define novel therapeutic strategies for the treatment of this kind of neuropathic pain.
Authors: Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti Journal: Inflammopharmacology Date: 2013-11-01 Impact factor: 4.473
Authors: Dena Zeraatkar; Matthew Adam Cooper; Arnav Agarwal; Robin W M Vernooij; Gareth Leung; Kevin Loniewski; Jared E Dookie; Muhammad Muneeb Ahmed; Brian Y Hong; Chris Hong; Patrick Hong; Rachel Couban; Thomas Agoritsas; Jason W Busse Journal: BMJ Open Date: 2022-08-04 Impact factor: 3.006